samedan logo
 
 
spacer
home > pmps > winter 2002 > intelligent packaging solutions for the distribution of bulk chemicals and pharmaceuticals
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Intelligent Packaging Solutions for the Distribution of Bulk Chemicals and Pharmaceuticals

To define 'intelligence' two or more people are needed to discuss and agree its meaning in this context. In the case of packaging this term is generally accepted by the industry to refer to packaging that exceeds the basic or obvious requirements of the product and that delivers something more; quite often this 'something more' refers to the product's life cycle.

The headline is only eleven words long yet it covers a vast subject that can only be briefly touched upon in any feature article. For the purposes of this article we will illustrate aspects of intelligent packaging solutions through all stages of development by focusing on the area of bulk or distribution packaging of chemicals and pharmaceutical products that can be classified as dry flowables, and that are stored and transported in a way that requires some form of palletisation.

Whatever the packaging medium - from the self-modifying, sophisticated barrier plastics to the humble fibreboard container - thoughtful and expert design can make the difference between fulfilling a function and exemplary, sometimes exceptional performance. Intelligent packaging solutions are therefore often rooted in the management of the initial design process and the thought behind this.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By David Tebworth, Marketing Services Manager at DS Smith Tri-Wall
David Tebworth's experience in transit and heavy duty packaging stretches back over 30 years, covering engineering, sales, customer service, design and marketing in his career with DS Smith Tri-Wall, a manufacturer of high performance corrugated fibreboard.

As Marketing Services Manager he carries responsibility for pan-European marketing, reporting to the European Sales & Marketing Director. David has been closely associated with DS Smith Tri-Wall's design team which has collected 12 Worldstars and 24 Starpack design awards over the last four years.

spacer
David Tebworth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Owen Mumford Launches New 2-Step Single-Use Auto-Injector Platform Aidaptus®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development. Aidaptus is a 2-step, spring-powered, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement